Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 8196256, 9 pages
https://doi.org/10.1155/2017/8196256
Review Article

Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence

Institute of Cardiology, Jagiellonian University School of Medicine and The John Paul II Hospital, Krakow, Poland

Correspondence should be addressed to Anetta Undas; lp.ude.rk-fyc@sadnumm

Received 23 January 2017; Revised 27 March 2017; Accepted 4 May 2017; Published 27 June 2017

Academic Editor: Dingeman C. Rijken

Copyright © 2017 Anetta Undas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. W. Mosesson, “Fibrinogen and fibrin structure and functions,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1894–1904, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. W. Weisel and R. I. Litvinov, “Mechanisms of fibrin polymerization and clinical implications,” Blood, vol. 121, no. 10, pp. 1712–1719, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Longstaff and K. Kolev, “Basic mechanisms and regulation of fibrinolysis,” Journal of Thrombosis and Haemostasis, vol. 13, no. 1, pp. S98–S105, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. M. R. Martinez, A. Cuker, A. M. Mills et al., “Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 306, no. 5, pp. L397–L404, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Mazur, R. Sobczyński, M. Za̧bczyk, P. Babiarczyk, J. Sadowski, and A. Undas, “Architecture of fibrin network inside thrombotic material obtained from the right atrium and pulmonary arteries: Flow and location matter,” Journal of Thrombosis and Thrombolysis, vol. 35, no. 1, pp. 127–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. T. Lord, “Molecular mechanisms affecting fibrin structure and stability,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 494–499, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Longstaff, C. Thelwell, S. C. Williams, M. M. C. G. Silva, L. Szabó, and K. Kolev, “The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: Kinetic and microscopic studies,” Blood, vol. 117, no. 2, pp. 661–668, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Blombäck, K. Carlsson, B. Hessel, A. Liljeborg, R. Procyk, and N. Åslund, “Native fibrin gel networks observed by 3D microscopy, permeation and turbidity,” Biochimica et Biophysica Acta (BBA)/Protein Structure and Molecular, vol. 997, no. 1-2, pp. 96–110, 1989. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Undas, “How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?” Seminars in Thrombosis and Hemostasis, vol. 42, no. 4, pp. 381–388, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Undas, “Fibrin clot properties and their modulation in thrombotic disorders,” Thrombosis and Haemostasis, vol. 112, no. 1, pp. 32–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. P. A. Evans, K. Hawkins, M. Lawrence et al., “Rheometry and associated techniques for blood coagulation studies,” Medical Engineering and Physics, vol. 30, no. 6, pp. 671–679, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Undas and R. A. S. Ariëns, “Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 12, pp. e88–e99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. I. Bridge, H. Philippou, and R. A. S. Ariëns, “Clot properties and cardiovascular disease,” Thrombosis and Haemostasis, vol. 112, no. 5, pp. 901–908, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Lisman, F. W. G. Leebeek, L. O. Mosnier et al., “Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis,” Gastroenterology, vol. 121, no. 1, pp. 131–139, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. E. J. Dunn, R. A. Ariëns, M. de Lange et al., “Genetics of fibrin clot structure: a twin study,” Blood, vol. 103, no. 5, pp. 1735–1740, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. K. F. Standeven, S. Uitte de Willige, A. M. Carter, and P. J. Grant, “Heritability of clot formation,” Seminars in Thrombosis and Hemostasis, vol. 35, no. 5, pp. 458–467, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. P. De Moerloose, F. Boehlen, and M. Neerman-Arbez, “Fibrinogen and the risk of thrombosis,” Seminars in Thrombosis and Hemostasis, vol. 36, no. 1, pp. 7–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Ajjan, B. C. B. Lim, K. F. Standeven, R. Harrand, S. Dolling, F. Phoenix et al., “Common variation in the C-terminal region of the fibrinogen β-chain: effects on fibrin structure, fibrinolysis and clot rigidity,” Blood, vol. 111, no. 2, pp. 643–650, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. G. J. Maghzal, S. O. Brennan, and P. M. George, “Fibrinogen B ? polymorphisms do not directly contribute to an altered in vitro clot structure in humans,” Thrombosis and Haemostasis, vol. 90, no. 6, pp. 1021–1028, 2003. View at Publisher · View at Google Scholar
  20. K. F. Standeven, P. J. Grant, A. M. Carter, T. Scheiner, J. W. Weisel, and R. A. S. Ariëns, “Functional analysis of the fibrinogen Aα Thr312Ala polymorphism: Effects on fibrin structure and function,” Circulation, vol. 107, no. 18, pp. 2326–2330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. S. U. De Willige, K. F. Standeven, H. Philippou, and R. A. S. Ariëns, “The pleiotropic role of the fibrinogen γ′ chain in hemostasis,” Blood, vol. 114, no. 19, pp. 3994–4001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. A. S. Ariëns, T.-S. Lai, J. W. Weisel, C. S. Greenberg, and P. J. Grant, “Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms,” Blood, vol. 100, no. 3, pp. 743–754, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. B. C. B. Lim, R. A. S. Ariëns, A. M. Carter, J. W. Weisel, and P. J. Grant, “Genetic regulation of fibrin structure and function: Complex gene-environment interactions may modulate vascular risk,” Lancet, vol. 361, no. 9367, pp. 1424–1431, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. A. S. Wolberg, D. M. Monroe, H. R. Roberts, and M. Hoffman, “Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk,” Blood, vol. 101, no. 8, pp. 3008–3013, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. A. S. Wolberg, “Thrombin generation and fibrin clot structure,” Blood Reviews, vol. 21, no. 3, pp. 131–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Undas, E. Stepien, W. Tracz, and A. Szczeklik, “Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis,” Journal of Thrombosis and Haemostasis, vol. 4, no. 5, pp. 973–975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Hoffman, “Alterations of fibrinogen structure in human disease,” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 6, no. 3, pp. 161–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Martinez, J. W. Weisel, and H. Ischiropoulos, “Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots,” Free Radical Biology and Medicine, vol. 65, pp. 411–418, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Parastatidis, L. Thomson, A. Burke et al., “Fibrinogen β-chain tyrosine nitration is a prothrombotic risk factor,” The Journal of Biological Chemistry, vol. 283, no. 49, pp. 33846–33853, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Undas, P. Kaczmarek, K. Sladek et al., “Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease: Beneficial effects of simvastatin treatment,” Thrombosis and Haemostasis, vol. 102, no. 6, pp. 1176–1182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Kwasny-Krochin, P. Gluszko, and A. Undas, “Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis,” Thrombosis Research, vol. 126, no. 1, pp. e11–e16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Owczarek, D. Cibor, K. Sałapa, M. K. Głowacki, T. Mach, and A. Undas, “Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: A novel prothrombotic mechanism,” Inflammatory Bowel Diseases, vol. 19, no. 12, pp. 2616–2624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. E.-M. Salonen, T. Vartio, K. Hedman, and A. Vaheri, “Binding of fibronectin by the acute phase reactant C-reactive protein,” Journal of Biological Chemistry, vol. 259, no. 3, pp. 1496–1501, 1984. View at Google Scholar · View at Scopus
  34. J. A. Heit, “Epidemiology of venous thromboembolism,” Nature Reviews Cardiology, vol. 12, no. 8, pp. 464–474, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Z. Goldhaber and H. Bounameaux, “Pulmonary embolism and deep vein thrombosis,” The Lancet, vol. 379, no. 9828, pp. 1835–1846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Kearon, E. A. Akl, A. J. Comerota et al., “Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, pp. e419S–e494S, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Gasior, D. Pres, W. Wojakowski et al., “Causes of hospitalization and prognosis in patients with cardiovascular diseases Secular trends in the years 2006–2014 according to the SILesian CARDiovascular (SILCARD) database,” Polskie Archiwum Medycyny Wewnetrznej, vol. 126, no. 10, pp. 754–762, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. A. L. C. La Corte, H. Philippou, and R. A. S. Arins, “Role of fibrin structure in thrombosis and vascular disease,” Advances in Protein Chemistry and Structural Biology, vol. 83, pp. 75–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. R. A. S. Ariëns, “Fibrin(ogen) and thrombotic disease,” Journal of Thrombosis and Haemostasis, vol. 11, supplement 1, pp. 294–305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. J. L. Curnow, M.-C. Morel-Kopp, C. Roddie, M. Aboud, and C. M. Ward, “Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay,” Journal of Thrombosis and Haemostasis, vol. 5, no. 3, pp. 528–534, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Lisman, P. G. De Groot, J. C. M. Meijers, and F. R. Rosendaal, “Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis,” Blood, vol. 105, no. 3, pp. 1102–1105, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. M. E. Meltzer, T. Lisman, P. G. De Groot et al., “Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1,” Blood, vol. 116, no. 1, pp. 113–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. E. Meltzer, T. Lisman, C. J. M. Doggen, P. G. De Groot, and F. R. Rosendaal, “Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis,” PLoS Medicine, vol. 5, no. 5, article no. e97, pp. 0751–0758, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Undas, K. Zawilska, M. Ciesla-Dul et al., “Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives,” Blood, vol. 114, no. 19, pp. 4272–4278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Traby, M. Kollars, L. Eischer, S. Eichinger, and P. A. Kyrle, “Prediction of Recurrent Venous Thromboembolism by Clot Lysis Time: A Prospective Cohort Study,” PLoS ONE, vol. 7, no. 12, Article ID e51447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Skov, J. J. Sidelmann, E.-M. Bladbjerg, J. Jespersen, and J. Gram, “Difference in fibrinolytic capacity in young patients with venous thrombosis or ischaemic stroke,” Blood Coagulation and Fibrinolysis, vol. 25, no. 1, pp. 61–66, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Zolcinski, M. Ciesla-Dul, and A. Undas, “Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism.,” Thrombosis and haemostasis, vol. 107, no. 6, pp. 1180–1182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Undas, M. Cieśla-Dul, T. Dra̧zkiewicz, and J. Sadowski, “Altered fibrin clot properties are associated with residual vein obstruction: Effects of lipoprotein(a) and apolipoprotein(a) isoform,” Thrombosis Research, vol. 130, no. 3, pp. e184–e187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Karasu, T. P. Baglin, R. Luddington, C. A. Baglin, and A. van Hylckama Vlieg, “Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis,” British Journal of Haematology, vol. 172, no. 6, pp. 947–953, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Siudut, M. Grela, E. Wypasek, K. Plens, and A. Undas, “Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome,” Journal of Thrombosis and Haemostasis, vol. 14, no. 4, pp. 784–793, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Lami, A. P. Cellai, E. Antonucci et al., “Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity,” Thrombosis Research, vol. 134, no. 3, pp. 737–741, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Zabczyk, K. Plens, W. Wojtowicz, and A. Undas, “Prothrombotic Fibrin Clot Phenotype Is Associated With Recurrent Pulmonary Embolism After Discontinuation of Anticoagulant TherapyHighlights,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 37, no. 2, pp. 365–373, 2017. View at Publisher · View at Google Scholar
  53. J. Hoekstra, A. H. C. Guimarães, F. W. G. Leebeek et al., “Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome,” Blood, vol. 115, no. 2, pp. 388–395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Z. Ke, X. Hao, W. Ning, Z. Mao-Heng, and F. Yu-Fei, “Fibrinolysis status in the Budd-Chiari syndrome in China,” Blood Coagulation and Fibrinolysis, vol. 26, no. 7, pp. 721–726, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Siudut, M. Świat, and A. Undas, “Altered fibrin clot properties in patients with cerebral venous sinus thrombosis: association with the risk of recurrence,” Stroke, vol. 46, no. 9, pp. 2665–2668, 2015. View at Publisher · View at Google Scholar
  56. I. Karska-Basta, A. Kubicka-TrzaSka, B. Romanowska-Dixon, and A. Undas, “Altered fibrin clot properties in patients with retinal vein occlusion,” Journal of Thrombosis and Haemostasis, vol. 9, no. 12, pp. 2513–2515, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. A. P. Cellai, D. Lami, S. Fedi et al., “A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion,” Atherosclerosis, vol. 224, no. 1, pp. 97–101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. P. M. Mannucci and M. Franchini, “Classic thrombophilic gene variants,” Thrombosis and Haemostasis, vol. 114, no. 5, pp. 885–889, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Krzek, M. Ciesla-Dul, M. Zabczyk, and A. Undas, “Fibrin clot properties in women heterozygous for factor v Leiden mutation: Effects of oral contraceptives,” Thrombosis Research, vol. 130, no. 4, pp. e216–e221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Van Langevelde, L. E. Flinterman, A. V. H. Vlieg, F. R. Rosendaal, and S. C. Cannegieter, “Broadening the factor V Leiden paradox: Pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum,” Blood, vol. 120, no. 5, pp. 933–946, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Colucci, B. M. Binetti, A. Tripodi, V. Chantarangkul, and N. Semeraro, “Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism,” Blood, vol. 103, no. 6, pp. 2157–2161, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Celinska-Lowenhoff, T. Iwaniec, M. Alhenc-Gelas, J. Musial, and A. Undas, “Arterial and venous thrombosis and pro-thrombotic fibrin clot phenotype in a Polish family with type 1 antithrombin deficiency (antithrombin krakow),” Thrombosis and Haemostasis, vol. 106, no. 2, pp. 379–381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. V. Pengo, G. Denas, S. J. Padayattil et al., “Diagnosis and therapy of antiphospholipid syndrome,” Polish Archives of Internal Medicine, vol. 125, no. 9, pp. 672–677, 2015. View at Publisher · View at Google Scholar
  64. V. Pengo, “Four good reasons to appreciate triple positivity,” Polish Archives of Internal Medicine, vol. 126, no. 1-2, pp. 7-8, 2016. View at Publisher · View at Google Scholar
  65. M. Celińska-Löwenhoff, T. Iwaniec, A. Padjas, J. Musiał, and A. Undas, “Altered fibrin clot structure/function in patients with antiphospholipid syndrome: Association with thrombotic manifestation,” Thrombosis and Haemostasis, vol. 112, no. 2, pp. 287–296, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Vikerfors, E. Svenungsson, A. Ågren et al., “Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome,” Thrombosis Research, vol. 133, no. 5, pp. 936–944, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Asztabski, E. Wypasek, M. Ząbczyk, and A. Undas, “Reduced plasma fibrin clot permeability and susceptibility to fibrinolysis are associated with increased intima-media thickness in patients with primary antiphospholipid syndrome,” Thrombosis Research, vol. 134, no. 5, pp. 945–951, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. T. A. Morris, J. J. Marsh, P. G. Chiles, W. R. Auger, P. F. Fedullo, and V. L. Woods Jr., “Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 11, pp. 1270–1275, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. T. A. Morris, J. J. Marsh, P. G. Chiles et al., “High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension,” Blood, vol. 114, no. 9, pp. 1929–1936, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. J. J. Marsh, P. G. Chiles, N.-C. Liang, and T. A. Morris, “Chronic thromboembolic pulmonary hypertension-associated dysfibrinogenemias exhibit disorganized fibrin structure,” Thrombosis Research, vol. 132, no. 6, pp. 729–734, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Roik, D. Wretowski, K. Irzyk, A. Łabyk, O. Dzikowska-Diduch, and P. Pruszczyk, “Familial chronic thromboembolic pulmonary hypertension in a mother and a son: Successful treatment with refined balloon pulmonary angioplasty,” Polskie Archiwum Medycyny Wewnetrznej, vol. 126, no. 12, pp. 1014–1016, 2016. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Kopeć, J. Stępniewski, M. Waligóra, M. Kurzyna, A. Biederman, and P. Podolec, “Staged treatment of central and peripheral lesions in chronic thromboembolic pulmonary hypertension,” Polskie Archiwum Medycyny Wewnetrznej, vol. 126, no. 1-2, pp. 97–99, 2016. View at Google Scholar · View at Scopus
  73. S. R. Kahn, I. Shrier, J. A. Julian et al., “Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis,” Annals of Internal Medicine, vol. 149, no. 10, pp. 698–707, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. A. C. Bouman, J. J. M. Smits, H. Ten Cate, and A. J. Ten Cate-Hoek, “Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome,” Journal of Thrombosis and Haemostasis, vol. 10, no. 8, pp. 1532–1538, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. Z. Krasiński, B. Krasińska, L. Dzieciuchowicz, T. Urbanek, and M. Gabriel, “Heparins in cancer-Associated venous thrombosis,” Polskie Archiwum Medycyny Wewnetrznej, vol. 126, no. 6, pp. 419–429, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Yeromonahos, R. Marlu, B. Polack, and F. Caton, “Antithrombin-independent effects of heparins on fibrin clot nanostructure,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 5, pp. 1320–1324, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Ząbczyk, M. Blombäck, J. Majewski et al., “Assays of fibrin network properties altered by VKAs in atrial fibrillation – Importance of using an appropriate coagulation trigger,” Thrombosis and Haemostasis, vol. 113, no. 4, pp. 851–861, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Blombäck, S. He, N. Bark, H. N. Wallen, and M. Elg, “Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate,” British Journal of Haematology, vol. 152, no. 6, pp. 758–765, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. S. He, M. Blombäck, N. Bark, H. Johnsson, and N. H. Wallen, “The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis,” Thrombosis and Haemostasis, vol. 103, no. 5, pp. 1076–1084, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Varin, S. Mirshahi, P. Mirshahi et al., “Improvement of thrombolysis by Rivaroxaban, an anti-Xa inhibitor. Potential therapeutic importance in patients with thrombosis,” Blood, vol. 112, p. 3031, 2008. View at Google Scholar
  81. R. Varin, S. Mirshahi, P. Mirshahi et al., “Whole blood clots are more resistant to lysis than plasma clots—greater efficacy of rivaroxaban,” Thrombosis Research, vol. 131, no. 3, pp. e100–e109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. C. T. Ammollo, F. Semeraro, F. Incampo, N. Semeraro, and M. Colucci, “Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor,” Journal of Thrombosis and Haemostasis, vol. 8, no. 4, pp. 790–798, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Undas, K. Brummel-Ziedins, and K. G. Mann, “Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid,” Journal of Thrombosis and Haemostasis, vol. 12, no. 11, pp. 1776–1787, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. R. A. Ajjan, K. F. Standeven, M. Khanbhai et al., “Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 5, pp. 712–717, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Undas, K. E. Brummel-Ziedins, and K. G. Mann, “Anticoagulant effects of statins and their clinical implications,” Thrombosis and Haemostasis, vol. 111, no. 3, pp. 392–400, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Undas, M. Celinska-Lowenhoff, T. Lowenhoff, and A. Szczeklik, “Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease,” Journal of Thrombosis and Haemostasis, vol. 4, no. 5, pp. 1029–1036, 2006. View at Publisher · View at Google Scholar
  87. W. M. Lijfering, J. S. Biedermann, M. J. H. A. Kruip, F. W. G. Leebeek, F. R. Rosendaal, and S. C. Cannegieter, “Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility,” Expert Review of Hematology, vol. 9, no. 11, pp. 1023–1030, 2016. View at Publisher · View at Google Scholar · View at Scopus